RS3PE syndrome induced by Pembrolizumab

Joint Bone Spine. 2021 Oct;88(5):105216. doi: 10.1016/j.jbspin.2021.105216. Epub 2021 May 14.

Authors

Aude Hansmaennel¹, Frank Verhoeven¹, Mickael Chouk¹, Clément Prati¹, François Aubin², Daniel Wendling³

Affiliations

¹ Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France.
² Service de dermatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France.
³ Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France. Electronic address: [email protected].

PMID: 33992788
DOI: 10.1016/j.jbspin.2021.105216

No abstract available

Keywords: Check point inhibitors; Pembrolizumab; RS3PE.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Edema
Humans
Syndrome
Synovitis*

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab